Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
November 07, 2018 09:42 ET
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
IBD Breakout Stocks Index Licensed by Innovator Capital Management Forms Basis for Latest ETF Listing
September 13, 2018 08:00 ET
|
Investor's Business Daily
LOS ANGELES, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Investor’s Business Daily (IBD), a leading financial news and research organization, today announced that Innovator Capital Management, LLC, has...
Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year
September 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash...
Why You Could Have Celiac Disease Without Knowing It
September 12, 2018 12:49 ET
|
Capital Digestive Care
Rockville, MD, Sept. 12, 2018 (GLOBE NEWSWIRE) -- By Brian Ciampa, MD Celiac disease is an autoimmune disorder affecting at least three million Americans, but it can be a difficult illness to pin...
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
September 06, 2018 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
July 26, 2018 09:00 ET
|
Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Completes $65 Million Series C Financing
June 06, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
May 31, 2018 16:05 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 07:30 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...